Wang Min, He Na, Tian Tian, Liu Lu, Yu Shuang, Ma Daoxin
Department of Hematology, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan 250012, China.
Biomed Res Int. 2014;2014:485645. doi: 10.1155/2014/485645. Epub 2014 May 11.
Since the discovery of JAK2V617F tyrosine kinase-activating mutation, several genes have been found mutated in myeloproliferative neoplasms (MPNs). FLT3-ITD, NPM1, and DNMT3A mutations frequently occurred in AML patients and have been found conferred with myeloproliferative neoplasms in mouse model. Therefore, we sought to search for mutations in JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in 129 cases including 120 classic MPN cases and 9 MDS/MPN cases. JAK2V617F mutation was found in 60% of the 120 classic MPNs. However, none of the patients displayed FLT3-ITD and NPM1 mutations; only 2 patients harbored DNMT3A R882 mutation. Further studies including whole-genome sequence will be conducted to investigate the possible involvement of these genes in MPN.
自从发现JAK2V617F酪氨酸激酶激活突变以来,已发现多个基因在骨髓增殖性肿瘤(MPN)中发生突变。FLT3-ITD、NPM1和DNMT3A突变在急性髓系白血病(AML)患者中频繁出现,并且在小鼠模型中已发现这些突变与骨髓增殖性肿瘤相关。因此,我们试图在129例患者中寻找JAK2V617F、FLT3-ITD、NPM1和DNMT3A的突变,其中包括120例经典MPN病例和9例骨髓增生异常综合征/MPN(MDS/MPN)病例。在120例经典MPN患者中,60%发现有JAK2V617F突变。然而,所有患者均未显示FLT3-ITD和NPM1突变;仅有2例患者存在DNMT3A R882突变。将开展包括全基因组测序在内的进一步研究,以调查这些基因在MPN中可能发挥的作用。